
The prevalence of diabetes is less in China compared to other developed and developing nations, but as it houses the largest population in the world, it provides plethora of opportunities to the pharmaceutical players entering in this market. Besides, amid increasing concerns towards health and increasing awareness about chronic diseases, like diabetes among the consumers, the diabetic drug market is expected to show decent growth in the coming years. Consequently, the oral diabetic drug market in the country is anticipated to grow at a CAGR of around 5.3% during 2012 - 2014, says our new research report “China Diabetes Market Analysis”.